Nivolumab and Ipilimumab as a Treatment for Malignant Pleural Mesothelioma
source: pixabay.com

Nivolumab and Ipilimumab as a Treatment for Malignant Pleural Mesothelioma

Based on new data, the European Medicines Agency’s Committee for Medicinal Products for Human Use has designated nivolumab and ipilimumab as the frontline treatment for malignant pleural mesothelioma (MPM) in…

Continue Reading Nivolumab and Ipilimumab as a Treatment for Malignant Pleural Mesothelioma
New Combination Treatment Demonstrates Improved Survival for Malignant Pleural Mesothelioma Patients
source: pixabay.com

New Combination Treatment Demonstrates Improved Survival for Malignant Pleural Mesothelioma Patients

The EMA has just recommended a combination therapy for patients with malignant pleural mesothelioma (MPM) that is considered unresectable. The treatment regimen includes nivolumab in combination with ipilimumab. This new…

Continue Reading New Combination Treatment Demonstrates Improved Survival for Malignant Pleural Mesothelioma Patients

The First Therapy in 15 Years has just Been Approved by the FDA for Malignant Pleural Mesothelioma!

The FDA has just approved the very first therapy for malignant pleural mesothelioma (MPM) in more than 15 years. It is the NovoTTF-100L System, developed by Novocure. Not only is…

Continue Reading The First Therapy in 15 Years has just Been Approved by the FDA for Malignant Pleural Mesothelioma!